Barr Confirms Decision in Azithromycin Inventorship Suit

WOODCLIFF LAKE, N.J., June 01, 2007 /PRNewswire-FirstCall/ --
Barr Pharmaceuticals, Inc. today confirmed that the Commercial
Court, Zagreb, Croatia announced a judgment requiring its
subsidiary, PLIVA d.d., to pay HRK 39 million (approximately USD $7
million) plus accrued interest, estimated at approximately HRK 43
million at the date of judgment (approximately USD $8 million), to
certain former employees in connection with the invention of a
process for manufacturing Azithromycin. The plaintiffs in the case
filed a complaint against PLIVA on August 22, 2001 seeking payment
on account of "author's compensation" pursuant to applicable law
and the Company's by-law on inventive activity related to the
"Procedure for obtaining azithromycin dehydrate from azithromycin
monohydrate" which is protected by Croatian patent number P921491
B1.

The Company said that it believes it has strong grounds for an
appeal of the decision and noted that the obligation to pay any
judgment will not arise unless the decision has been affirmed on
appeal.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical
company that operates in more than 30 countries worldwide and is
engaged in the development, manufacture and marketing of generic
and proprietary pharmaceuticals, biopharmaceuticals and active
pharmaceutical ingredients. A holding company, Barr operates
through its principal subsidiaries: Barr Laboratories, Inc.,
Duramed Pharmaceuticals, Inc. and PLIVA d.d. The Barr group of
companies markets more than 115 generic and 25 proprietary products
in the U.S. and more than 1,200 products globally outside of the
U.S.

Forward-Looking Statements

Except for the historical information contained herein, the
statements made in this press release constitute forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements can be identified by their use of words
such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "intends," "estimates" and
other words of similar meaning. Because such statements inherently
involve risks and uncertainties that cannot be predicted or
quantified, actual results may differ materially from those
expressed or implied by such forward-looking statements depending
upon a number of factors affecting the Company's business. These
factors include, among others: the difficulty in predicting the
timing and outcome of legal proceedings, including patent-related
matters such as patent challenge settlements and patent
infringement cases; the outcome of litigation arising from
challenging the validity or non- infringement of patents covering
our products; the difficulty of predicting the timing of FDA
approvals; court and FDA decisions on exclusivity periods; the
ability of competitors to extend exclusivity periods for their
products; our ability to complete product development activities in
the timeframes and for the costs we expect; market and customer
acceptance and demand for our pharmaceutical products; our
dependence on revenues from significant customers; reimbursement
policies of third party payors; our dependence on revenues from
significant products; the use of estimates in the preparation of
our financial statements; the impact of competitive products and
pricing on products, including the launch of authorized generics;
the ability to launch new products in the timeframes we expect; the
availability of raw materials; the availability of any product we
purchase and sell as a distributor; the regulatory environment in
the markets where we operate; our exposure to product liability and
other lawsuits and contingencies; the increasing cost of insurance
and the availability of product liability insurance coverage; our
timely and successful completion of strategic initiatives,
including integrating companies (such as PLIVA d.d.) and products
we acquire and implementing our new SAP enterprise resource
planning system; fluctuations in operating results, including the
effects on such results from spending for research and development,
sales and marketing activities and patent challenge activities; the
inherent uncertainty associated with financial projections; our
expansion into international markets through our PLIVA acquisition,
and the resulting currency, governmental, regulatory and other
risks involved with international operations; our ability to
service our significantly increased debt obligations as a result of
the PLIVA acquisition; changes in generally accepted accounting
principles; and other risks detailed in our SEC filings, including
in our Transition Report on Form 10-K/T for the six months ended
December 31, 2006.

The forward-looking statements contained in this press release
speak only as of the date the statement was made. The Company
undertakes no obligation (nor does it intend) to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except to the extent
required under applicable law.